Belantamab mafodotin Disease Interactions

Belantamab has caused ocular toxicity resulting in changes in vision, including severe vision loss and corneal ulcer, and symptoms such as blurred vision and dry eyes. Caution and close monitoring is advised in patients with preexisting visual disturbances. Ophthalmic exams should be performed at baseline, prior to each dose, and promptly for new or worsening symptom. Due to the risk of ocular toxicity, this drug is only available through a restricted program under the Risk Evaluation and Mitigation Strategy (REMS).

Belantamab has not been studied in patients with moderate or severe hepatic impairment. Caution is advised. No dosage modification is required in patients with mild hepatic impairment.

Belantamab has not been studied in patients with severe renal impairment, or end-stage renal disease not on dialysis or in dialysis. Caution is advised. No dosage modification is required in patients with mild or moderate renal impairment.